Bolt Biotherapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Bolt Biotherapeutics, Inc. (BOLT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 764.96 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 753.67K shares, a 39.32% increase year-over-year.
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 540.97K shares, a 95.68% decline year-over-year.
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 12.53M shares, a 18.66% increase year-over-year.
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 10.56M shares, a 39.96% increase year-over-year.
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 709.27K shares, a 24.15% increase from fiscal 2024.
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 571.31K shares, a 94.69% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 10.76M shares, a 46.43% increase from fiscal 2022.
- Bolt Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.35M shares, a 23.27% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 764.96K shares 10-Q · filed 2026-08-11 | |||||||
| 2026-03-31 | 753.67K shares 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | 709.27K shares 10-K · filed 2026-03-12 | |||||||
| 2025-09-30 | 533.19K shares 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | 633.69K shares 10-Q · filed 2026-08-11 | |||||||
| 2025-03-31 | 540.97K shares 10-Q · filed 2026-05-12 | 10.82M shares 10-Q · filed 2025-05-12 | ||||||
| 2024-12-31 | 571.31K shares 10-K · filed 2026-03-12 | 11.42M shares 10-K · filed 2025-03-24 | ||||||
| 2024-09-30 | 615.41K shares 10-Q · filed 2025-11-12 | 12.30M shares 10-Q · filed 2024-11-12 | ||||||
| 2024-06-30 | 630.04K shares 10-Q · filed 2025-08-14 | 12.63M shares 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | 12.53M shares 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | 10.76M shares 10-K · filed 2025-03-24 | |||||||
| 2023-09-30 | 10.98M shares 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | 10.88M shares 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | 10.56M shares 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | 7.35M shares 10-K · filed 2024-03-21 | |||||||
| 2022-09-30 | 7.42M shares 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | 7.93M shares 10-Q · filed 2023-08-07 | |||||||
| 2022-03-31 | 7.55M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 5.96M shares 10-K · filed 2023-03-29 | |||||||
| 2021-09-30 | 5.20M shares 10-Q · filed 2021-11-09 | 5.20M shares 10-Q · filed 2022-11-10 | ||||||
| 2021-06-30 | 5.10M shares 10-Q · filed 2021-08-12 | 5.10M shares 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | 5.05M shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 19.08M shares 10-K · filed 2022-03-30 | |||||||
| 2020-09-30 | 19.06M shares 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | 17.24M shares 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | 12.09M shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |